Atezolizumab Suppliers & Bulk Manufacturers

Available Forms: Intravenous infusion

Available Strengths: 1200 mg/20 mL

Reference Brands: Tecentriq® (EU & US)

Category: Oncology Cancer Care

Atezolizumab is available in Intravenous infusion and strengths such as 1200 mg/20 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Atezolizumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Atezolizumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Atezolizumab (Tecentriq®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma, NSCLC, and triple-negative breast cancer. Provided as sterile intravenous infusion vials (1200 mg/20 mL), Atezolizumab is produced under EU-GMP and USFDA standards. Offered for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody restores anti-tumor immunity by blocking PD-L1, making it a vital immuno-oncology therapy in US and European cancer treatment portfolios.